While Myriad Genetics, Inc has underperformed by -0.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -23.88%, with highs and lows ranging from $29.30 to $14.34, whereas the simple moving average fell by -36.85% in the last 200 days.
On December 10, 2024, UBS started tracking Myriad Genetics, Inc (NASDAQ: MYGN) recommending Neutral. A report published by Leerink Partners on December 09, 2024, Downgraded its rating to ‘Market Perform’ for MYGN. Morgan Stanley also rated MYGN shares as ‘Equal-Weight’, setting a target price of $32 on the company’s shares in an initiating report dated September 19, 2024. Wells Fargo Initiated an Overweight rating on August 28, 2024, and assigned a price target of $35. Scotiabank initiated its ‘Sector Outperform’ rating for MYGN, as published in its report on June 27, 2024. Jefferies’s report from June 03, 2024 suggests a price prediction of $20 for MYGN shares, giving the stock a ‘Underperform’ rating. Leerink Partners also rated the stock as ‘Outperform’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Myriad Genetics, Inc (MYGN)
Further, the quarter-over-quarter increase in sales is 11.15%, showing a positive trend in the upcoming months.
One of the most important indicators of Myriad Genetics, Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -16.39% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.73, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and MYGN is recording 821.86K average volume. On a monthly basis, the volatility of the stock is set at 5.08%, whereas on a weekly basis, it is put at 8.16%, with a loss of -11.37% over the past seven days. Furthermore, long-term investors anticipate a median target price of $21.75, showing growth from the present price of $14.50, which can serve as yet another indication of whether MYGN is worth investing in or should be passed over.
How Do You Analyze Myriad Genetics, Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.76%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 100.22% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
MYGN shares are owned by institutional investors to the tune of 100.22% at present.
